In another trial, patients were administered nivolumab (Opdivo®), a checkpoint inhibitor that targets the PD‐1/PD‐L1 pathway, and it was approved to be used alone or in combination with ipilimumab for a subset of patients with advanced CRC that has MSI‐H [266, 267]. The gene discussed is PDCD1; the disease is colorectal carcinoma.